2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)

3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (COMPLETED)

NCT06083207

A Phase I/II, Multicenter, Open-label, First-in-human Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma (CIBI3003A101)

NCT06050707

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach (MAESTRO)

NCT05952557

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

NCT05949684

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial

NCT05868174

A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors (177Lu-TLX250-001)

NCT05855200

A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (WITHDRAWN)

3004 - Melbourne, Southbank - Alfred Health (WITHDRAWN)

NCT05800665

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer (GO44537)

NCT05730036

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

NCT05725291

First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors (AMT-116-01)

NCT05694936

A Phase II Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (VADER Study).

NCT05533697

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (mRNA-4359-P101)

NCT05523947

A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors (YH32367-101)

WA6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)

NCT05450744

A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma (IPAX-2)

NCT05267626

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (CP-AU-007-01)

NCT05254171

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma (ASPIRE)

NSW2485 - Tweed Heads - The Tweed Hospital (WITHDRAWN)

NCT05215340

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

NCT05169177

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy (ROCK-RT)

NCT05006716

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies (CaDAnCe-101)

NCT04994717

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) (2023-503640-14--20190360)

NCT04928846

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868)

NCT04901234

Adaptive RadioTherapy for Locally Advanced OroPharynx Cancer (ART-OPC) A Phase II Randomized Trial

NCT04771130

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (2021-003285-12--BGB-11417-103)

NCT04686305

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03) (DL03)

VIC3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)

SA5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (TERMINATED)

NCT04594642

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma (D7400C00006)

NCT04521231

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL (2023-506136-32--20180257)

NCT04429542

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (BCA101X1101)

NCT04419649

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (KER050-MD-201)

NCT03970447

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM-AGILE)

NCT03816254

A Phase 1, Open-label, Dose Finding Study of CC-95251, a Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers (U1111-1224-8251--CC-95251-ST-001)

NCT03486873

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (3475-587)

4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

NCT02582697

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)

3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)

NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)

ACTRN12625000361404

A Phase 1, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FO-004 in Patients with advanced solid tumours.

ACTRN12624001164583

Not Applicable

Exploring the Utility of Peritoneal Tumour DNA to Detect Clinically Occult Peritoneal Metastasis in Locally Advanced Colon Cancer (DETECT-PM) in adults

ACTRN12623001126606

Phase I/II clinical trial evaluating the safety and efficacy of allogeneic cytomegalovirus-specific T cells in combination with pembrolizumab for recurrent and newly diagnosed glioblastoma multiforme (TCaP)

ACTRN12623001077651

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2. (EMITT-1)

ACTRN12623000902695

Not Applicable

MRI Guided Stereotactic Focal Ablation of Prostate Cancer investigating feasibility, Toxicity and Patient Reported Outcomes. (MR-Ablate)

ACTRN12623000874617

Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (Biomarcer-2)

ACTRN12623000552684

OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection

ACTRN12623000096651

LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS

ACTRN12622001232729

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (The-ANZHIT-2-study)

ACTRN12622000180718

Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (SPACE-FLOT): An international multicentre cohort study

ACTRN12621001444875

A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (The-SOCRATES-HCC-Study)

ACTRN12621000659808

Not Applicable

Feasibility of Magnetic Resonance Image Guided Single Fraction Preoperative Radiotherapy for Early Breast Cancer (RICE)

ACTRN12621000586819

A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer (TROG-20.01-CHEST-RT)

ACTRN12621000223831

Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (PREACH-M-(PREACH-M)

NCT05182931

A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

PD-1/PD-L1	32%
PD-1	26%
PD-L1	14%
EGFR	12%
VEGF	7%
ERBB2	6%
CTLA4	6%
CD19	5%
TIGIT	4%
VEGFA	4%
ER	4%
oestrogen axis	4%
PARP	4%
androgen axis	3%
ERBB3	3%
CDK4	3%
MET	3%
KRAS	3%
KRAS G12C	3%
CD20	3%
DNA methyltransferase	3%
Trop2	3%
CLDN18.2	2%
HDAC	2%
FGFR3	2%
Nectin4	2%
CYP17A1	2%
LAT1	2%
LAT2	2%
CDK6	2%
ERAP1	2%
BCMA	2%
cereblon	2%
B7H3	2%
RET	2%
AR	2%
PRMT5	2%
BTK	2%
Bcl2	2%
LAG3	2%
PI3K	2%
PI3K delta	2%
PI3Kalpha	2%
mTOR	2%
mTORC1	2%
mTORC2	2%
VEGFR1	1%
VEGFR2	1%
VEGFR3	1%
STEAP1	1%
SMO	1%
IRAK4	1%
FR-alpha	1%
ALK	1%
EGFR CDAC	1%
GPR65	1%
DLL3	1%
MAT2A	1%
HRAS G12C	1%
NRAS G12C	1%
CDK4 selective	1%
PRAME	1%
GPRC5D	1%
DNA-dependent protein kinase	1%
CS1	1%
CD44v9	1%
IDO	1%
4-1BB	1%
IL-2	1%
ATM	1%
FGFR1	1%
FGFR1/2/3	1%
FGFR2	1%
FGFR4	1%
KIT	1%
PDGFR	1%
VEGFR	1%
SIRPa	1%
XPO1	1%
GM-CSF	1%
BRAF	1%
BRAF V600	1%
MEK	1%
RAF	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters